Related Experiment Video
Updated: Jul 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against
Per Johansson1,2,3,4, Paulina Jonéus1, Sophie Langenskiöld2,5
1Department of Statistics, Uppsala University, Uppsala, Sweden.
Abstract:
Regulatory authorities are recognizing the need for real-world evidence (RWE) as a complement to randomized controlled trials in the approval of drugs. However, RWE needs to be fit for regulatory purposes. There is an ongoing discussion regarding whether pre-publication of a protocol on appropriate repositories, e.g. ClinicalTrials.gov, would increase the quality of RWE or not. This paper illustrates that an observational study based on a pre-published protocol can entail the same level of detail as a protocol for a randomized experiment. The strategy is exemplified by designing a comparative effectiveness evaluation of abiraterone acetate against enzalutamide in clinical practice. These two cancer drugs are prescribed to patients with advanced prostate cancer. Two complementary designs, including pre-analysis plans, were published before data on outcomes and proxy-outcomes were obtained. The underlying assumptions are assessed and both analyses show an increased mortality risk from being prescribed abiraterone acetate compared to enzalutamide.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Criteria for Causality: Bradford Hill Criteria - II
Dose-Response Relationship: Potency and Efficacy
Causality in Epidemiology
Cancer Survival Analysis
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

